Abstract
Type 2 diabetes mellitus is a worldwide health problem. Adequate glycemic control can help to prevent many chronic diabetic complications. Despite the availability of several classes of oral hypoglycemic agents and insulin, many patients fail to achieve adequate glycemic control. Incretins are gut hormones produced in response to ingestion of nutrients. Glucagon-like peptide-1 (GLP-1), one of the incretin hormones, has pleiotropic actions on the control of blood glucose. Clinical trials with the incretin mimetic and Dipeptidyl peptidase-IV inhibitors demonstrate promising results in the improvement of glucose homeostasis.
| Original language | English |
|---|---|
| Pages (from-to) | 943-954 |
| Number of pages | 12 |
| Journal | Journal of the Medical Association of Thailand |
| Volume | 91 |
| Issue number | 6 |
| Publication status | Published - Jun 2008 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- DPP-IV inhibitors
- GLP-1
- Incretins
- Type 2 diabetes
Fingerprint
Dive into the research topics of 'Incretins: The novel therapy of type 2 diabetes'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver